What is the official website of Dynavax GmbH ?

The official website of Dynavax GmbH is http://www.dynavax.com.

What is Dynavax GmbH's cybersecurity risk score?

Dynavax GmbH has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Dynavax GmbH experienced?

According to Rankiteo, Dynavax GmbH currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Dynavax GmbH been affected by any supply chain cyber incidents ?

According to Rankiteo, Dynavax GmbH has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Dynavax GmbH have SOC 2 Type 1 certification ?

According to Rankiteo, Dynavax GmbH is not certified under SOC 2 Type 1.

Does Dynavax GmbH have SOC 2 Type 2 certification ?

According to Rankiteo, Dynavax GmbH does not hold a SOC 2 Type 2 certification.

Does Dynavax GmbH comply with GDPR ?

According to Rankiteo, Dynavax GmbH is not listed as GDPR compliant.

Does Dynavax GmbH have PCI DSS certification ?

According to Rankiteo, Dynavax GmbH does not currently maintain PCI DSS compliance.

Does Dynavax GmbH comply with HIPAA ?

According to Rankiteo, Dynavax GmbH is not compliant with HIPAA regulations.

Does Dynavax GmbH have ISO 27001 certification ?

According to Rankiteo,Dynavax GmbH is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Dynavax GmbH operate in ?

Dynavax GmbH operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Dynavax GmbH have ?

Dynavax GmbH employs approximately 85 people worldwide.

Does Dynavax GmbH own any subsidiaries ?

Dynavax GmbH presently has no subsidiaries across any sectors.

How many LinkedIn followers does Dynavax GmbH have ?

Dynavax GmbH's official LinkedIn profile has approximately 3,825 followers.

What is the NAICS classification code for Dynavax GmbH ?

Dynavax GmbH is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Dynavax GmbH have a Crunchbase profile ?

No, Dynavax GmbH does not have a profile on Crunchbase.

Does Dynavax GmbH have a LinkedIn profile ?

Yes, Dynavax GmbH maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/dynavax-gmbh.

How many cybersecurity incidents has Dynavax GmbH experienced ?

As of October 1, 2026, Rankiteo reports that Dynavax GmbH has not experienced any cybersecurity incidents.

How many peer or competitor companies does Dynavax GmbH have ?

Dynavax GmbH has an estimated 5,771 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Dynavax GmbH

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Dynavax GmbH Vendor Cyber Rating & Cyber Score

dynavax.com

Add Your Compliance Badge

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza,

Dynavax GmbH

Dynavax GmbH CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Dynavax GmbH Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Dynavax GmbH

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Dynavax GmbH in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Dynavax GmbH in 2026.

Incident Types Dynavax GmbH vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Dynavax GmbH in 2026.

Incident History - Dynavax GmbH (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Dynavax GmbH Subsidiaries

Parent Company

Dynavax GmbH

Pharmaceutical Manufacturing

Website: http://www.dynavax.com

Company Size: 85

No subsidiary data available for this company.

Loading…

Dynavax GmbH Similar Companies

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, with 140 years of history, present in 140 countries worldwide, with a turnover of 4.88 billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants and is distributed across six continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Servier

servier.com

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Loading…

NEWS

Dynavax GmbH CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-103591

SUMMARY

DeepWiki-Open through commit d92819a contains an unauthenticated arbitrary file read vulnerability in the GET /codemap/file endpoint via the repo_url parameter. Attackers can supply a non-URL repo_url value to bypass path containment checks and read any file accessible to the API process by specifying absolute file paths.

Published

Date2026-09-30

Updated

Date2026-09-30

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-103590

SUMMARY

QloApps through 1.7.0 contains a reflected cross-site scripting vulnerability in the back-office room type editor's length of stay fields. Attackers can induce authenticated administrators to submit crafted POST requests with malicious payloads in restriction_min_los and restriction_max_los parameters, executing arbitrary JavaScript in the victim's administrative session.

Published

Date2026-09-30

Updated

Date2026-09-30

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N

cvss4

Base Score: 5.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:L/VI:L/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.7

Exploitability

2.3

REFERENCES

CVE-2026-103589

SUMMARY

QloApps through 1.7.0 contains a reflected cross-site scripting vulnerability in the back-office room type editor that fails to escape room_num, floor, and comment field values in input attributes. Attackers can induce authenticated back-office users to submit crafted POST requests with malicious payloads to execute arbitrary JavaScript in the victim's administrative session.

Published

Date2026-09-30

Updated

Date2026-09-30

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N

cvss4

Base Score: 5.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:L/VI:L/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.7

Exploitability

2.3

REFERENCES

CVE-2026-103588

SUMMARY

QloApps through 1.7.0 contains a reflected cross-site scripting vulnerability in the exceptions field of the back-office Transplant a module form. Attackers can craft a malicious link containing JavaScript payload in the exceptions parameter that executes in an authenticated administrator's session when the victim follows the link.

Published

Date2026-09-30

Updated

Date2026-09-30

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N

cvss4

Base Score: 5.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:L/VI:L/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.7

Exploitability

2.3

REFERENCES

CVE-2026-103587

SUMMARY

QloApps through 1.7.0 contains a reflected cross-site scripting vulnerability in the back-office Hotel Reservation System Book Now search, where date_to and id_room_type parameters are copied into template variables without validation. Attackers can craft a malicious link containing JavaScript payload in these parameters that executes in an authenticated administrator's session when the victim follows the link.

Published

Date2026-09-30

Updated

Date2026-09-30

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N

cvss4

Base Score: 5.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:L/VI:L/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.7

Exploitability

2.3

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Dynavax GmbH Vendor Cyber Rating & Cyber Score

Dynavax GmbH A.I CyberSecurity Scoring

Dynavax GmbH CyberSecurity News & History

Dynavax GmbH Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Dynavax GmbH

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Dynavax GmbH vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Dynavax GmbH (X = Date, Y = Severity)

Dynavax GmbH Subsidiaries

Parent Company

Dynavax GmbH

Dynavax GmbH Similar Companies

UCB

MENARINI Group

Lonza

Bristol Myers Squibb

Glenmark Pharmaceuticals

Eli Lilly and Company

Hikma Pharmaceuticals

Ipca Laboratories Limited

Servier

Dynavax GmbH CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Dynavax GmbH CyberSecurity News & History

Dynavax GmbH Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Dynavax GmbH

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Dynavax GmbH vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Dynavax GmbH (X = Date, Y = Severity)

Dynavax GmbH Subsidiaries

Parent Company

Dynavax GmbH

Dynavax GmbH Similar Companies

UCB

MENARINI Group

Lonza

Bristol Myers Squibb

Glenmark Pharmaceuticals

Eli Lilly and Company

Hikma Pharmaceuticals

Ipca Laboratories Limited

Servier

Dynavax GmbH CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo